Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

zer's decision not to launch a

phase 3 program.

Eric Castaldi, Chief Financial Officer at NicOx, said: "During the third quarter of 2008 we have achieved considerable success in the development of naproxcinod, while keeping the necessary control on expenses. We are very encouraged by the positive top-line results from the 302 phase 3 study, which comfortably met its efficacy endpoints and supported naproxcinod's non-detrimental effect on blood pressure, as well as by the good long term safety data observed in the 301 extension study.

We have also significantly advanced our pre-launch activities for naproxcinod, through the signature of an agreement for the manufacture of naproxcinod capsules for future commercialization, and are confident that the New Drug Application will be filed in mid 2009 as planned. We remain focused on the finalization of the clinical program for naproxcinod and look forward to the results of the 303 phase 3 study and the 111 and 112 Ambulatory Blood Pressure Monitoring studies in the coming months. As anticipated, our cash balance at the end of the third quarter is EUR124.8 million, which will enable us to fully finance the remaining clinical trials for naproxcinod and continue to advance the development of the other compounds in our portfolio."

Financial summary of the first nine months of 2008:

Revenues were EUR2.9 million for the nine months ended September 30, 2008, compared to EUR18.4 million during the same period in 2007. These revenues were due to the allocation of payments received from Pfizer Inc and Merck & Co., Inc. following the agreements signed with the two companies in the fields of ophthalmology and hypertension, respectively.

For the first nine months of 2008, operating expenses were EUR60.4 million, compared to EUR39.0 million for the corresponding period of 2007. As expected, the majority of these expenses were due to research and development costs related to naproxcinod, NicOx'
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... presenting at the Baird Healthcare Conference in New York.  ... Financial Officer, will be making a presentation on PAREXEL ... Wednesday, Sept. 3, 2014. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... nerves in your ear could improve the health of ... the University of Leeds used a standard TENS machine ... electrical pulses to the tragus, the small raised flap ... of the ear canal. , The stimulation changed the ... reducing the nervous signals that can drive failing hearts ...
(Date:8/20/2014)... August 20, 2014 GraphDB™ ... today including improvements to the enterprise replication cluster, ... for Lucene, SOLR and Elasticsearch. This release happens ... high performance triplestore – GraphDB™ was formerly known ... deploying the only mature enterprise resilient RDF triplestore ...
Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... RICHMOND, Virginia, ROSH HA,AYIN, Israel, June 16 ,EnzySurge ... advanced,chronic wound management, recently announced the formation of ... and practitioners with diversified expertise in chronic wounds.,The ... MD, PhD, Diane L.,Krasner, PhD RN, FAAN, Joseph ...
... June 16 Alexandria Real Estate,Equities, Inc. (NYSE: ... 100 life science,executives from around the world on ... environmentally sustainable operations in the San Diego life,science ... being held in,conjunction with the Biotechnology Industry Organization,s ...
... data management product for the, hospital ... connection, BOTHELL, Wash., June 16 Cardiac ... flagship HeartCentrix(R) data,management product for the hospital market. ... across all facilities within a,hospital network. Cardiac Science ...
Cached Biology Technology:EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 2EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 3EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 4Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 2Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 3Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 4Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 2Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 3Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 4
(Date:8/20/2014)... screening outcomes of approximately 3 million infants, a team ... the University of Massachusetts Medical School, have shown that ... successfully implemented across public health newborn screening programs. Data ... 20 issue of the Journal of the American ... of SCID in newborns is higher than previously thought ...
(Date:8/20/2014)... has awarded the Oklahoma Medical Research Foundation a five-year, ... and the bacteria,s effects on humans. , For ... colleagues have studied the human immune response to anthrax ... Immunology. The original funding came soon after anthrax-laced letters ... the terrorist attacks of Sept. 11, 2001. , ...
(Date:8/20/2014)... EUGENE, Ore. -- When are athletes who have suffered ... of Oregon study has found that high school athletes ... within 60 days experience a significant regression in their ... , The regression, as seen in changes in their ... of 19 athletes. Ten of the 12 had returned ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... effects of antioxidants such as vitamin C. Scientists at ... of lipid the ability of antioxidants, such as ascorbic ... against the generation of potential cancer-forming compounds in the ... “Our results illustrate how diet can influence gastric biochemistry? ...
... differs from other individuals, the level at which those ... person to another, scientists have learned. And though some ... different populations ?Asians versus Europeans, for instance ?more of ... the biological meaning of "race." , The findings ...
... Al Gore's film, An Inconvenient Truth, has generated greater ... the more rapid warming that has occurred within major ... 10 degrees hotter than their surroundings. These metropolitan hot ... can stress the animals and plants that make their ...
Cached Biology News:Individuals and populations differ in gene activity levels, not just genes 2City ants take the heat 2
... MultiScribe Reverse Transcriptase is a recombinant ... transcriptase. MultiScribe Reverse Transcriptase is similar ... in its recommended usage. MuLV reverse ... polymerase that uses single-stranded RNA as ...
... determination of digitonin and digoxin. Physical form: Lyophilized ... and 0.06% NaCl Preparation Note: Sodium iodide ... Res. Commun., 19, 755 (1965). Unit Definition: ... phosphorus from ATP per min at pH 7.4 ...
... protease from human rhinovirus (HRV 3C) is ... line of restriction grade proteases. The recombinant ... protein, which recognizes the same cleavage site ... 22 KDa size of the protease, optimal ...
... IEC Centra CL3 series is designed ... research and clinical applications at a ... package includes quick connect rotors and ... yet intuitive interface allows you to ...
Biology Products: